Diabetes guidelines recommend these GLP-1 RAs as pharmacologic agents in patients with ASCVD or with high-risk indicators for cardiovascular disease
What could be better than to gain dual benefits of lowering sugar while reducing weight simultaneously
It is especially this kind of adipose tissue that is believed to drive a large part of the pathological effects of excess body weight ( The reductions in ROS and systemic inflammation, in combination with improvements in the other cardiometabolic parameters, are also thought to mediate the substantiated but so far formally unconfirmed kidney-protective effects of GLP-1 RAs, which may also directly or indirectly carry a HF-related benefit, considering that CKD is a prominent risk factor for HF (von Scholten et al., 2022)
Your healthcare team can provide personalised advice based on your individual circumstances, ensuring that any decision to stop GLP-1 therapy is safe, well-planned, and supported by appropriate monitoring and alternative management strategies where needed
Compared with the 1.5 mg dulaglutide group, body weight was significantly decreased in the 3.0 mg (ETD 0.9, 95% CI 1.4 to 0.4 kg
When muscle mass drops too much: Your metabolism slows down , so you burn fewer calories You lose strength, stability, and energy You may regain fat more easily after stopping the medication You increase your risk of long-term frailty and poor body composition The goal isnt just to lose weight its to lose fat while keeping (or gaining) strength
